Biotechnology company Virax Biolabs Group Limited (NASDAQ: VRAX) on Wednesday announced a new distribution agreement with Europa Biosite for the commercialisation of its ImmuneSelect Research Use portfolio in the United Kingdom and Ireland. The distribution will be managed through Cambridge Bioscience, a subsidiary of European supplier of life science products and services Europa Biosite, facilitating Virax's entry into these key markets.

ImmuneSelect is a portfolio designed for research into adaptive immunity, containing products not intended for diagnostic purposes but instead focused on investigational use. The offerings include peptide pools that target epitopes from pathogens, optimized to stimulate T cell responses. Initial peptide pools cover a range of pathogens such as SARS-CoV-2, SARS-CoV-2 MHC-1 (CD8), Lyme Disease, Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV) and Epstein-Barr Virus (EBV). The portfolio also includes Recombinant Antibodies for detecting cytokines and biomarkers, suitable for applications like Flow Cytometry, ELISA and ELISpot/Fluorospot.

Virax Biolabs' partnership with Europa Biosite is a strategic move to leverage the European distributor's market presence, as it encompasses six key distribution companies with a collective reach across 16 European countries. This collaboration is aimed at maximizing sales growth through targeted regional solutions and close relationships with local suppliers.

The company's core focus remains on advancing T-cell-based diagnostic technologies to better understand immune responses, particularly for conditions like Long COVID and other chronic diseases related to immune dysregulation. The ImmuneSelect portfolio aligns with the company's broader objective of providing a platform for immunology profiling that aids in post-viral syndrome diagnostics.